The UOKiK has granted conditional consent to ZakÅ‚ady Farmaceutyczne Polpharma’s takeover of ZakÅ‚ady Farmaceutyczne Polfa in Warszawa. Polpharma is owned by Genefar, and Polfa Warszawa is the state budget company belonging to Polski Holding Farmaceutyczny. Both companies are involved with the production and sale of pharmaceutical products.
The UOKiK found that the merger would lead to decreased competition in the markets for three antithrombotic drugs, as well as possible price increases. The terms of the consent thus require Polpharma to sell all its rights to three drugs within 18 months of the decision date. The drugs are: Polocard or Acard (antithrombotic drugs), Cipronex or Proxacin (fluorochinolones) and Sulfacetamidum natrium or Sulfacetamidum WZF 10% HEC.
Full content: UOKiK Press Release
Related content: The AZ Judgment: A Green Light for Further Action on Pharma and IP (Sean-Paul Brankin, Crowell & Moring)
Featured News
OpenAI Board Denies Receiving Formal Bid from Elon Musk
Feb 12, 2025 by
CPI
Thomas Kauper, Former DOJ Antitrust Leader, Dies at 89
Feb 12, 2025 by
CPI
BlackRock’s Acquisition of Preqin Secures UK Regulatory Approval
Feb 12, 2025 by
CPI
NFL Sued Over Bluesky Ban by Fans Citing Antitrust Violations
Feb 12, 2025 by
CPI
Warburg Pincus Strikes $1 Billion Deal to Acquire Vermont Information Processing
Feb 12, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon